Tolerability and Pharmacokinetics of Lobeglitazone (CKD-501), a Peroxisome Proliferator-Activated Receptor-gamma Agonist: A Single-Dose, Double-Blind, Randomized Control Study in Healthy Male Korean Subjects.

Trial Profile

Tolerability and Pharmacokinetics of Lobeglitazone (CKD-501), a Peroxisome Proliferator-Activated Receptor-gamma Agonist: A Single-Dose, Double-Blind, Randomized Control Study in Healthy Male Korean Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Oct 2011

At a glance

  • Drugs Lobeglitazone (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 31 Oct 2011 Results published in the Clinical Therapeutics.
    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top